StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR – Free Report) in a research report sent to investors on Sunday morning. The brokerage issued a sell rating on the stock.
Separately, Piper Sandler reiterated an “overweight” rating and set a $4.50 target price on shares of InspireMD in a research report on Tuesday, September 17th.
Check Out Our Latest Stock Analysis on InspireMD
InspireMD Trading Down 2.9 %
Institutional Inflows and Outflows
An institutional investor recently bought a new position in InspireMD stock. Affiance Financial LLC bought a new position in InspireMD, Inc. (NYSE:NSPR – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned about 0.74% of InspireMD at the end of the most recent quarter. Hedge funds and other institutional investors own 44.78% of the company’s stock.
About InspireMD
InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
Recommended Stories
- Five stocks we like better than InspireMD
- How to Calculate Stock Profit
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.